CG Oncology, Inc. (CGON) SEC filings

CGONNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 6, 2026Score 5/30

$74.40+4.25 (+6.06%)

Close on Nov 13, 2026Market cap $6.59BP/E –Yield –

SEC filings

40 of CG Oncology's most recent filings on SEC EDGAR

Document	Form	Period	Filed	Source
Quarterly report	10-Q	Sep 30, 2026	Nov 6, 2026	SEC EDGAR
Current report	8-K	Nov 6, 2026	Nov 6, 2026	SEC EDGAR
Quarterly report	10-Q	Jun 30, 2026	Aug 6, 2026	SEC EDGAR
Current report	8-K	Aug 6, 2026	Aug 6, 2026	SEC EDGAR
Current report	8-K	Jun 4, 2026	Jun 8, 2026	SEC EDGAR
Current report	8-K	May 20, 2026	May 26, 2026	SEC EDGAR
Quarterly report	10-Q	Mar 31, 2026	May 8, 2026	SEC EDGAR
Current report	8-K	May 8, 2026	May 8, 2026	SEC EDGAR
Proxy statement	DEF 14A	Apr 23, 2026	Apr 24, 2026	SEC EDGAR
Current report	8-K	Apr 13, 2026	Apr 13, 2026	SEC EDGAR
Annual report	10-K	Dec 31, 2025	Feb 27, 2026	SEC EDGAR
Current report	8-K	Feb 27, 2026	Feb 27, 2026	SEC EDGAR
Current report	8-K	Jan 13, 2026	Jan 13, 2026	SEC EDGAR
Current report	8-K	Jan 9, 2026	Jan 9, 2026	SEC EDGAR
Current report	8-K	Nov 22, 2025	Nov 26, 2025	SEC EDGAR
Current report	8-K	Nov 10, 2025	Nov 14, 2025	SEC EDGAR
Quarterly report	10-Q	Sep 30, 2025	Nov 14, 2025	SEC EDGAR
Current report	8-K	Nov 14, 2025	Nov 14, 2025	SEC EDGAR
Current report	8-K	Sep 9, 2025	Sep 9, 2025	SEC EDGAR
Current report	8-K	Sep 5, 2025	Sep 5, 2025	SEC EDGAR
Quarterly report	10-Q	Jun 30, 2025	Aug 8, 2025	SEC EDGAR
Current report	8-K	Aug 8, 2025	Aug 8, 2025	SEC EDGAR
Current report	8-K	Jul 7, 2025	Jul 11, 2025	SEC EDGAR
Current report	8-K	Jun 5, 2025	Jun 6, 2025	SEC EDGAR
Quarterly report	10-Q	Mar 31, 2025	May 13, 2025	SEC EDGAR
Current report	8-K	May 13, 2025	May 13, 2025	SEC EDGAR
Current report	8-K	Apr 26, 2025	Apr 28, 2025	SEC EDGAR
Proxy statement	DEF 14A	Jun 5, 2025	Apr 25, 2025	SEC EDGAR
Annual report	10-K	Dec 31, 2024	Mar 28, 2025	SEC EDGAR
Current report	8-K	Mar 28, 2025	Mar 28, 2025	SEC EDGAR
Current report	8-K	Mar 24, 2025	Mar 24, 2025	SEC EDGAR
Current report	8-K	Jan 9, 2025	Jan 10, 2025	SEC EDGAR
Current report	8-K	Dec 5, 2024	Dec 5, 2024	SEC EDGAR
Quarterly report	10-Q	Sep 30, 2024	Nov 12, 2024	SEC EDGAR
Current report	8-K	Nov 12, 2024	Nov 12, 2024	SEC EDGAR
Quarterly report	10-Q	Jun 30, 2024	Aug 8, 2024	SEC EDGAR
Current report	8-K	Aug 8, 2024	Aug 8, 2024	SEC EDGAR
Current report	8-K	May 24, 2024	May 24, 2024	SEC EDGAR
Current report	8-K	May 9, 2024	May 9, 2024	SEC EDGAR
Quarterly report	10-Q	Mar 31, 2024	May 9, 2024	SEC EDGAR

Where these numbers come from

Parsed from the XBRL in CG Oncology's annual and quarterly filings with the SEC
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is CGON.

Compare: CGON vs TCRX · CGON vs CRBU · CGON vs MOLN · CGON vs CRIS · CGON vs RLAY

Revenue growth183.6% · median 1.6%

Operating margin-4293.5% · median -2246.8%

Net margin-3851.1% · median -2219.2%

Company	Revenue	Growth
RLAY	$10.35M	+23.9%
CRBU	$9.44M	+1.6%
CGON	$6.17M	+183.6%
TCRX	$5.19M	-38.4%
MOLN	–	–
CRIS	–	–

Company

Next earnings (est.): Feb 26, 2027, before open
Exchange: Nasdaq
Industry: Biological Products, (No Diagnostic Substances)
Fiscal year ends: December 31
Employees: 142
Held by institutions: 100.0%
Auditor: Ernst & Young LLP
SEC CIK: 1991792

Advertisement
300 × 250

See a number that looks wrong?